Our goal is to unlock the exosome revolution based on our unique innovation platform that harnesses the homing properties of this new class of drug candidates.
We are developing naive and engineered exosome-based therapies, with two proprietary lead naive regenerative therapy candidates in gastrointestinal healing and organ regrowth, both with high unmet medical needs and large market potential.
:quality(80)/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2023/12/pipe-a-jour.png)
